FDA Expands Use of Approved Breast Cancer Drug : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

FDA Expands Use of Approved Breast Cancer Drug

February 1, 2010

Washington D.C. (RPRN) 02/01/10 — Provides oral regime for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.

“This drug combination of Tykerb plus Femara provides women being treated for advanced breast cancer with an important treatment option. This entirely oral treatment regimen works by targeting both HER2 and the hormone receptors, thereby slowing the cancer cells’ ability to grow or spread,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, in the FDA’s Center for Drug Evaluation and Research.

Women with HER2-positive disease receiving the Tykerb plus Femara combination more than doubled the time they lived without the cancer progressing compared with those receiving Femara alone (35 weeks vs. 13 weeks). Women in the company sponsored study were randomized to receive Tykerb plus Femara or Femara alone. It is too early to determine whether an improvement in overall survival will be observed in the clinical trial.

Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.

Tykerb was initially approved in combination with a chemotherapy drug, Xeloda (capecitabine) in 2007. This combination was used to treat women with advanced breast cancer tumors with the HER2 protein who had received prior treatment with chemotherapy drugs, including an anthracycline and a taxane, and Herceptin (trastuzumab), an anti-cancer antibody used to treat HER2-positive advanced breast cancer.

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer. The most commonly reported side effects of the combination were diarrhea, rash, nausea and fatigue. Treatment with Tykerb also has been associated with decreases in heart function, liver damage, and lung tissue inflammation. Fetal harm may occur if used to treat advanced breast cancer in pregnant women. Patients should talk to their health care provider about the potential side effects, drug interactions, and other medical conditions.

 

Tykerb is marketed by Collegeville, Pa.-based GlaxoSmithKline.
Femara is marketed by Lebanon, Pa.-based Novartis AG.

 

For more information:

 

FDA Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

 

National Cancer Institute – Breast Cancer
http://www.cancer.gov/cancertopics/types/breast

 

RSS Feed for FDA News Releases [what is RSS?]

About the author:

FDA is an agency within the Department of Health and Human Services and consists of seven centers and offices

Click here to see all news from this author/company

Filed Under: FDA- Pharmaceutical news, Health and Fitness, Food-Nutrition, Lifestyle, PRESS RELEASE

RUSH PR NEWS newswire and press release services at rushprnews.com / Anne Howard annehowardpublicist.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Yoga on Water...Without Water

Toronto, Ontario 08/26/15 ·  - Standup Paddleboarding (SUP) is one of the...

Hilltop Christmas Trees Available for Home Delivery

New York, NY 08/19/15 · The perfect Christmas tree is the centre piece...

MONTREAL MEDIA ALERT: Moment™'s world premiere at McLean’s Pub: compact karaoke soundbar

MONTREAL 08/17/15 · Moment™'s world premiere, compact karaoke soundbar  to revolutionize...

Network Heroes Offers Full HIPAA Audits In Las Vegas, NV

Las Vegas, NV 08/14/15 · Network Heroes Partners with the Best HIPAA Compliance...

Dynamic Blending Specialists, LLC Kicks Off an Indiegogo, Inc. Crowdfunding Campaign

South Jordan, UT 08/14/15 · – Dynamic Blending Specialists (DBS) a cosmetic formula...

Aspect Imaging launch one-touch MRI at WMIC, 2015

Shoham, Israel 08/12/15 · Aspect's advanced one-touch MRI will be presented at...

Growing Problem of Anti-Semitism in the United Church of Canada

OTTAWA, ON, Canada 08/10/15 · Proposals Before The United Church Of Canada General...

Thriveon Earns Respected Technology Industry Credential

New Ulm, MN 08/06/15 · CompTIA Managed Services Trustmark™ signifies commitment to industry...

Portable Road Weather Information System (RWIS) Available

Nashville, TN 08/03/15 · Digital Traffic Systems, Inc. of Ashland, Virginia, announces...

Dry Paddleboarding Across Canada

Uxbridge, ON 08/03/15 · Uxbridge, August 3rd, 2015 - Standup Paddleboarding (SUP)...